This session will provide an update on the management of IgE-mediated food allergy, focussing on the evolving field of oral immunotherapy. We will correlate basic mechanisms of therapy with observed clinical benefits in various patient populations. We will discuss the rationale as well as barriers for initiating therapy early in infants. We will also review the rational behind the recent change in recommendations with regards to the need to visit the emergency department after injection of intramuscular epinephrine.
Dr Bégin is a professor and FRQS senior clinical scholar in the Department of Medicine, section of allergy and immunology at Université de Montréal. His research program focusses on the clinical development and evaluation of new interventions in children and adults with food allergy. He has published over 140 peer-reviewed articles. He practices at the CHUM and CHU Sainte-Justine in Montreal, where he is the founder and director of the oral immunotherapy unit.